LMB763 + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Steatohepatitis NASH
Conditions
Non-alcoholic Steatohepatitis NASH
Trial Timeline
Oct 24, 2016 → Sep 19, 2018
NCT ID
NCT02913105About LMB763 + Placebo
LMB763 + Placebo is a phase 2 stage product being developed by Novartis for Non-alcoholic Steatohepatitis NASH. The current trial status is terminated. This product is registered under clinical trial identifier NCT02913105. Target conditions include Non-alcoholic Steatohepatitis NASH.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02913105 | Phase 2 | Terminated |
Competing Products
20 competing products in Non-alcoholic Steatohepatitis NASH